Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | INSRR | P14616 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | DAPK1 | P53355 | 1/20 | 1.00 |
| ▸ | MERTK | Q12866 | 1/20 | 1.00 |
| ▸ | DAPK2 | Q9UIK4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168588 | 1.00 | ALK (1.00) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL21459035 | 1.00 | ALK (1.00) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL20168624 | 0.95 | ALK (0.90) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL20168720 | 0.95 | ALK (0.90) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL20168664 | 0.95 | ALK (0.90) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL23116612 | 0.93 | ALK (0.87) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL21391668 | 0.93 | ALK (0.87) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL21459161 | 0.92 | ALK (0.86) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL21473698 | 0.92 | ALK (0.86) | ALKDAPK3INSRINSRRLTK | |
| SCHEMBL20182981 | 0.92 | ALK (1.00) | ALKDAPK3INSRINSRRLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043821-B | Aminopyrimidines as ALK inhibitors | 密歇根大学董事会 | 2024-08-06 | — | — | CN | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115043821-A | Aminopyrimidines as ALK inhibitors | 密歇根大学董事会 | 2022-09-13 | — | — | CN | disclosed |
| EP-4001273-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-109715620-B | Aminopyrimidines as ALK inhibitors | 密歇根大学董事会 | 2022-05-06 | — | — | CN | disclosed |